Results 111 to 120 of about 138,032 (344)

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis. [PDF]

open access: yes, 2009
The approach to treating autoimmune disorders is currently undergoing a significant change in focus. As therapies are developed that are more precise in targeting the pathogenesis for these diseases, patients experience significantly fewer side effects ...
Sands, Jacob, Tuscano, Joseph M
core   +2 more sources

Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice [PDF]

open access: yes, 2019
We investigated the contribution of human platelets to macrophage effector properties in the presence of lipopolysaccharide (LPS), as well as the beneficial effects and time frame for platelet transfusion in septic animals.
Carestia, Agostina   +9 more
core   +1 more source

Molecular stratification of antiphospholipid syndrome through integrative analysis of the whole‐blood RNA transcriptome

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Antiphospholipid syndrome (APS) is a thrombo‐inflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)‐positive patients using whole‐blood transcriptomics.
Amala Ambati   +13 more
wiley   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

Immune Thrombocytopenia in Children

open access: yesZdorovʹe Rebenka, 2013
.
L. Ya. Dubey   +5 more
doaj   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo   +10 more
wiley   +1 more source

Clinical and Laboratory Analysis of Children Who Follow Up with Thrombocytopenia: A Retrospective Study

open access: yesGüncel Pediatri
Introduction: Platelets are cells that play an important role in the first phase of hemostasis, where the clot plug is formed. Disorders in the number or function of platelets can lead to bleeding.
Yasemin Denkboy Öngen, Birol Baytan
doaj   +1 more source

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia

open access: yesHaematologica, 2017
Primary immune thrombocytopenia is an autoimmune disorder characterized by increased platelet destruction and insufficient platelet production without another identified underlying disorder.
Douglas B. Cines   +10 more
doaj   +1 more source

Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia [PDF]

open access: hybrid, 2021
Ricardo Viana   +10 more
openalex   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy